From PsychonautWiki
(Redirected from SSk-2C-B)
Jump to navigation Jump to search
Summary sheet: Βk-2C-B
Chemical Nomenclature
Common names βk-2C-B, beta-keto 2C-B, bk-2C-B
Systematic name 2-Amino-1-(4-bromo-2,5-dimethoxyphenyl)ethan-1-one
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 50 mg
Light 60 - 80 mg
Common 80 - 100 mg
Strong 100 - 150 mg
Heavy 150 mg +
Total 8 - 12 hours
Onset 20 - 70 minutes

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


βk-2C-B (also known as Bk-2C-B, or beta-keto 2C-B) is a novel psychedelic substance of the phenethylamine class. It is a structural analog of 2C-B.

Subjective effects include open and closed-eye visuals, time distortion, euphoria, and ego loss. Compared to 2C-B, its effects are often described as being considerably more stimulating and less psychedelic with a significantly longer duration.

βk-2C-B is relatively uncommon and has little to no history of human usage prior to its 2014 distribution by online vendors as a research chemical.[1][2]

Very little data exists about the pharmacological properties, metabolism, and toxicity of βk-2C-B. As a result, users are advised to approach this novel and poorly understood hallucinogenic substance with the proper amount of precaution and harm reduction practices if choosing to use it.

History and culture

The original synthesis of βk-2C-B is not available on the public record. However, based on information gathered from internet forums and scientific studies, it appears that it was not originally synthesized in the 1970s by Alexander Shulgin like many 2C-x compounds.

The first reliable mention of βk-2C-B does not appear until 2004, with it playing only a minor role in a scientific study as a precursor of 5-HT2A serotonin receptor agonists.[3] The next confirmed mention of the substance can be dated to December 2007. At that time, the user "King Kong" of the bluelight.org forum opened a thread for information and discussion of bk-2c-bβk-2C-B. There was a brief discussion about the possible instability of the molecule, but not more than 20 posts were written in the following 6 years.[4]

βk-2C-B received more attention since 2013, when the first experience reports appear on the internet following its appearance on the research chemical market via "online head shops" start selling it as "a legal replacement for 2C-B".[5]

Overall, βk-2c-b is considered a relatively obscure substance, even among research chemicals.[5][6] An analysis of the Google search history between 2013-2017 shows that 2C-B was consistently searched 3-4 times more often βk-2C-B.[7] Since 2017, βk-2C-B seems to have almost completely disappeared from the open market.


βk-2C-B, or beta-keto 2C-B, is a substituted phenethylamine featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain. βk-2C-B contains the structure of 2C-B substituted with a ketone group at the beta carbon of the structure (R1). βk-2C-B contains methoxy functional groups CH3O- attached to carbons R2 and R5 as well as a bromine atom attached to carbon R4 of the phenyl ring. βk-2C-B belongs to the 2C family of phenethylamines which contain methoxy groups on the 2 and 5 positions of the benzene ring.[8]


Further information: Serotonergic psychedelic

βk-2C-B likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from its efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational βk-2C-B use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because Bk-2C-B is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried Bk-2C-B suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

As with psychedelics in general, βk-2C-B is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of βk-2C-B are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). Bk-2C-B presents cross-tolerance with all psychedelics, meaning that after the consumption of βk-2C-B, all psychedelics will have a reduced effect.

Legal status


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Canada: βk-2C-B is a Schedule III controlled substance as of October 12, 2016.
  • Germany: βk-2C-B is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016.[9][10] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[11]
  • Japan: βk-2C-B is a controlled substance in Japan effective March 25th, 2015.[12]
  • Switzerland: βk-2C-B is a controlled substance specifically named under Verzeichnis E.[13]
  • Sweden: βk-2C-B was classified as a narcotic on April 5, 2019.[14]
  • United Kingdom: It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.[15]
  • United States: βk-2C-B is unscheduled in the U.S., but may be considered an analogue of 2C-B under the Federal Analogue Act and thus a Schedule I drug.{{https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2019/april/atta-nya-amnen-klassas-som-narkotika/}}

See also

External links


  1. Power, J. D., Kavanagh, P., O’Brien, J., Barry, M., Twamley, B., Talbot, B., Dowling, G., Brandt, S. D. (June 2015). "Test purchase, identification and synthesis of 2‐amino‐1‐(4‐bromo‐2, 5‐dimethoxyphenyl)ethan‐1‐one (bk‐2C‐B)". Drug Testing and Analysis. 7 (6): 512–518. doi:10.1002/dta.1699. ISSN 1942-7603. 
  2. Frison, G., Odoardi, S., Frasson, S., Sciarrone, R., Ortar, G., Romolo, F. S., Strano Rossi, S. (15 July 2015). "Characterization of the designer drug bk-2C-B (2-amino-1-(bromo-dimethoxyphenyl)ethan-1-one) by gas chromatography/mass spectrometry without and with derivatization with 2,2,2-trichloroethyl chloroformate, liquid chromatography/high-resolution mass spectrometry, and nuclear magnetic resonance". Rapid communications in mass spectrometry: RCM. 29 (13): 1196–1204. doi:10.1002/rcm.7211. ISSN 1097-0231. 
  3. Glennon, R. A., Bondarev, M. L., Khorana, N., Young, R., May, J. A., Hellberg, M. R., McLaughlin, M. A., Sharif, N. A. (18 November 2004). "Beta-oxygenated analogues of the 5-HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane". Journal of Medicinal Chemistry. 47 (24): 6034–6041. doi:10.1021/jm040082s. ISSN 0022-2623. 
  4. Bluelight.ru - The Big & Dandy βK-2C-B Thread - Part 1 | https://www.bluelight.org/xf/threads/the-big-dandy-%CE%B2k-2c-b-thread-part-1.694585
  5. 5.0 5.1 Beharry, S., Gibbons, S. (1 October 2016). "An overview of emerging and new psychoactive substances in the United Kingdom". Forensic Science International. 267: 25–34. doi:10.1016/j.forsciint.2016.08.013. ISSN 0379-0738. 
  6. Last checked in 09/20 via Google Scholar |https://scholar.google.de/scholar?hl=de&as_sdt=0%2C5&q=%22bk-2c-b%22&btnG=&oq=%22bk-2c-%22
  7. Last checked in 09/20 via Google Trends | https://trends.google.com/trends/explore?date=all&q=%CE%B2k-2C-B,%22bk-2C-B%22,%222C-B%22
  8. #20 2C-B PiHKAL 
  9. "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 11, 2019. 
  10. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019. 
  11. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019. 
  12. "危険ドラッグの成分16物質を新たに指定薬物に指定" (in Japanese). 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]. Retrieved May 2, 2022.
  13. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  14. "Åtta nya ämnen klassas som narkotika" (in Northern Sami). Folkhälsomyndigheten[The Swedish Public Health Agency]. Retrieved January 4, 2021. 
  15. Psychoactive Substances Act 2016